Research Article
Phase I/II Clinical Trial of Autologous Activated Platelet-Rich Plasma (aaPRP) in the Treatment of Severe Coronavirus Disease 2019 (COVID-19) Patients
Table 1
Summary of autologous activated PRP characteristics
| | 1. PRP preparation |
| | Initial blood volume | 24 mL | | Anticoagulant | Sodium citrate 1.2% (wt/V) | | System | Open | | Centrifugation | Yes | | Number | 2 | | Speed | 1000 rpm (188 g), 3000 rpm (1690 g) | | Final PRP volume | 6 mL |
| | 2. Autologous activated PRP characteristics |
| | PRP type | 310–00–11 | | Mean platelet volume (MPV) | — | | Red blood cells | — | | White blood cells | — | | Neutrophils | — | | Lymphocytes | — | | Monocytes | — | | Eosinophils | — | | Basophils | — | | Activation | Calcium activator |
| | 3. Application characteristics |
| | Formulation type | Liquid | | Administration route | Intravenous (IV) | | Dosage | Up to 3 dosages with a day of interval (day 1, 3, 5) | | Volume | 6 mL PRP + 100 mL 0.9% NaCl | | Dose (number of injected platelets (range)) | 0 cell number |
| | 4. Other remarkable PRP and study features |
| | The final product of activated autologous PRP (contains no platelet) was administered (IV) |
|
|
